FULL PRODUCT CATALOG LOG IN REGISTER

Funding
Research Fund
Status
NIH SBIR Phase I, “Immunoassays for metabolites of AA
epoxygenases”.

Completed

NIH SBIR Phase I, “Mutagenicity/genotoxicity assays with
endogenous PGHS-2”.
Completed
NIH SBIR Phase I, “Microarrays of X. laevis genes: A tool for
molecular toxicology”.
Completed
NIH R15 grant, "Role of cytochrome P450 in isoflavone
metabolism".
Completed
NIH SBIR Phase II, “Immunoassays for metabolites of AA
epoxygenases”.
Completed
NIH SBIR Phase I, “Targeted antibody microarrays: A tool for
toxicoproteomics”.
Completed
NIH SBIR Phase II, “Mutagenicity/genotoxicity assays with PGHS- 2”.
Completed
Michigan Life Science Corridor Fund partner company “The
mechanism of eukaryotic arsenic transport and resistance”.
Completed
NIH SBIR Phase II, “Microarrays of X. laevis genes: A tool for
molecular toxicology”.
Completed
NIH SBIR Phase I “Fetal alcohol syndrome biomarkers by antibody microarray”.
Completed
STTR Phase I “A molecular signature of cell invasion in breast
cancer”.
Completed
SBIR Phase II “Targeted antibody microarrays: a tool for
toxicoproteomics”.
Completed
SBIR Phase I “Antibody and protein microarrays for early cancer
detection”.
Completed
SBIR contract Phase II “Diagnostic ELISA to measure prostate cancer biomarker in serum”.
Active
NOVEL HYPERTENSION/STROKE BIOMARKERS AND DRUG DEVELOPMENT

PRODUCTS
 
LICENSING OF OUR PATENTED TECHNOLOGIES

DETROIT R&D, INC.
Metro Center for High Technology Bldg. | 2727 Second Ave. Suite 4113 | Detroit, MI 48201
Phone: 313.961.1606 | Fax: 313.963.7130 | Email: info@detroitrandd.com

Copyright © 2001-2010 Detroit R & D, Inc. All Rights Reserved.